9 January 2024
GENinCode Plc
("GENinCode" or the "Company")
Result of General Meeting, Issue of Equity and Total Voting Rights
GENinCode plc (AIM: GENI), the polygenics company focused on the prevention of cardiovascular disease ("CVD"), announces that all resolutions put to Shareholders at the General Meeting held earlier today in connection with the placing, subscription and retail offer announced by the Company on 21 December 2023 were duly passed.
| Resolution | For | Against | Withheld | Total votes cast | |||
| | | Number of votes | % | Number of votes | % | Number of votes |
|
| 1 | Ordinary resolution to authorise the directors to allot shares |
31,947,121 |
99.99% |
2,846 |
0.01% |
7,085 |
31,949,967
|
| 2 | Special resolution to authorise the directors to disapply pre-emption rights |
31,947,121 |
99.99% |
2,846 |
0.01% |
7,085 |
31,949,967
|
(1) Any proxy appointments, which gave discretion to the Chairman have been included in the 'For' votes total.
(2) Votes "For" and "Against" any resolution are expressed as a percentage of votes validly cast for that resolution.
(3) A vote "Withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against", nor in the aggregate figure of total votes cast.
Issue of Equity and Total Voting Rights
Following shareholder approval at the general meeting and conditional on admission, 67,576,000 new ordinary shares have been allotted pursuant to the Placing, 1,147,560 new ordinary shares pursuant to the Retail Offer and 12,424,000 pursuant to the Subscription.
The Company has therefore allotted a total of 81,147,560 new ordinary shares in connection with the Fundraising.
Admission is expected to take place at 8.00 a.m. on or around 10 January 2024.
Following Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 176,964,426 with each Ordinary Share carrying the right to one vote. There are no shares held in treasury and therefore, following Admission, the total number of voting rights in the Company will be 176,964,426.
The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure, Guidance and Transparency Rules.
Capitalised terms used in this announcement have the meaning given to them in the announcement of the Placing and Subscription dated 21 December 2023, unless otherwise defined in this announcement.
For more information visit www.genincode.com
Enquiries:
| GENinCode Plc | www.genincode.com or via Walbrook PR |
| Matthew Walls, CEO Paul Foulger, CFO |
|
| | |
| Cavendish Capital Markets Limited | Tel: +44 (0)20 7220 0500 |
| Giles Balleny / Dan Hodkinson (Corporate Finance) Nigel Birks (ECM) Dale Bellis / Michael Johnson (Sales)
| |
| Walbrook PR Limited Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage | Tel: 020 7933 8780 or Mob: +44 (0)7876 741 001 / +44 (0)7747 515 393 / +44 (0) 7867 984 082 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.